Table 2.
Comparison of long-term delay-adjusted incidence trends with and without VA adjustment for SEER-9 areas among males, 1975–2005*
| Joinpoint analyses (1975–2005)† | |||||||||||
| Trend 1 | Trend 2 | Trend 3 | Trend 4 | Trend 5 | |||||||
| Cancer site | Race | Years | APC‡ | Years | APC‡ | Years | APC‡ | Years | APC‡ | Years | APC‡ |
| All sites | All | 1975–1989 | 1.3§ | 1989–1992 | 5.2 | 1992–1995 | −4.8§ | 1995–2001 | 0.3 | 2001–2005 | –1.8§ |
| All sites (VA adjusted) | All | ‖ | ‖ | ‖ | ‖ | 2001–2005 | −1.7§ | ||||
| All sites | White | 1975–1989 | 1.4§ | 1989–1992 | 5.0§ | 1992–1995 | −5.0§ | 1995–2001 | 0.6§ | 2001–2005 | −1.6§ |
| All sites (VA adjusted) | White | ‖ | ‖ | ‖ | ‖ | 2001–2005 | −1.5§ | ||||
| All sites | Black | 1975–1981 | 2.8§ | 1981–1989 | 0.7 | 1989–1992 | 6.8§ | 1992–2005 | −1.7§ | ||
| All sites (VA adjusted) | Black | ‖ | ‖ | 1989–1992 | 7.6§ | 1992–1995 | −2.9 | 1995–2005 | −1.3§ | ||
| Oral cavity and pharynx | All | 1975–2005 | −1.2§ | ||||||||
| Oral cavity and pharynx (VA adjusted) | All | ‖ | |||||||||
| Colon and rectum | All | 1975–1985 | 1.1§ | 1985–1991 | −1.2§ | 1991–1995 | −3.1§ | 1995–1998 | 1.9 | 1998–2005 | −2.8§ |
| Colon and rectum (VA adjusted) | All | ‖ | ‖ | ‖ | ‖ | ‖ | |||||
| Liver and IBD | All | 1975–2005 | 3.6§ | ||||||||
| Liver and IBD (VA adjusted) | All | ‖ | |||||||||
| Lung and bronchus | All | 1975–1982 | 1.5§ | 1982–1991 | −0.5 | 1991–2005 | −1.8§ | ||||
| Lung and bronchus (VA adjusted) | All | ‖ | ‖ | −1.7§ | |||||||
| Melanoma of the skin | All | 1975–1985 | 5.4§ | 1985–2000 | 3.4§ | 2000–2003 | −0.2 | 2003–2005 | 7.7§ | ||
| Melanoma of the skin (VA adjusted) | All | ‖ | ‖ | ‖ | 2003–2005 | 7.9§ | |||||
| Prostate | All | 1975–1988 | 2.6§ | 1988–1992 | 16.5§ | 1992–1995 | −11.5§ | 1995–2001 | 2.1§ | 2001–2005 | −4.4§ |
| Prostate (VA adjusted) | All | ‖ | ‖ | ‖ | ‖ | 2001–2005 | −4.3§ | ||||
| Urinary bladder | All | 1975–1986 | 0.9§ | 1986–2005 | 0.0 | ||||||
| Urinary bladder (VA adjusted) | All | ‖ | ‖ | ||||||||
| Kidney and renal pelvis | All | 1975–2005 | 1.8§ | ||||||||
| Kidney and renal pelvis (VA adjusted) | All | ‖ | |||||||||
| Non–Hodgkin lymphoma | All | 1975–1991 | 4.2§ | 1991–2005 | 0.4§ | ||||||
| Non–Hodgkin lymphoma (VA adjusted) | All | ‖ | ‖ | ||||||||
| Leukemia | All | 1975–2005 | 0.1 | ||||||||
| Leukemia (VA adjusted) | All | ‖ | |||||||||
VA adjustment was generated for SEER-9 regions. Source: SEER-9 areas covering about 10% of the US population (Connecticut, Hawaii, Iowa, Utah, and New Mexico and the metropolitan areas of San Francisco, Detroit, Atlanta, and Seattle–Puget Sound). VA = US. Department of Veterans Affairs; SEER = Surveillance, Epidemiology, and End Results; APC = annual percent change; NOS = not otherwise specified. IBD = intrahepatic bile duct.
Joinpoint analyses with up to four joinpoints are based on rates per 100 000 persons and were age adjusted to the 2000 US standard population (19 age groups—Census p25–1130). Joinpoint Regression Program, v 3.3.1, April 2008, National Cancer Institute.
APC is based on delay-adjusted rates that were age adjusted to the 2000 US standard population (19 age groups—Census p25–1130).
APC is statistically significantly different from zero (P < .05, two-sided Student t test.).
APCs are same as delay adjusted.